Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404397 | 0.82 | — | — | |
| SCHEMBL11463790 | 0.79 | — | — | |
| SCHEMBL2051373 | 0.77 | KDM4E (0.35) | DAOKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL13992470 | 0.74 | CHEK1 (0.31) | TYMPKDM4EGAAALDH1A1 | |
| SCHEMBL12044557 | 0.73 | — | — | |
| SCHEMBL10021065 | 0.65 | PDE3B (0.45) | TYMPKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL13527427 | 0.64 | ALDH1A1 (0.38) | GAAALDH1A1 | |
| SCHEMBL24000182 | 0.63 | GRIN2D (0.48) | DAOKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8480586 | 0.63 | DYRK1A (0.52) | TYMPKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11780540 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983020-B1 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024080872-A1 | STRAINED BICYCLONONENES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-04-18 | — | — | WO | disclosed |
| US-20240051925-A1 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2024-02-15 | — | — | US | disclosed |
| EP-3788032-B1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-01-24 | — | — | EP | disclosed |
| EP-4232436-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | Madrigal Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023158305-A1 | MASKED IL12 PROTEIN | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-08-24 | — | — | WO | disclosed |
| CN-116406356-A | Process for the preparation of 6- (4-nitro-phenoxy) -2H-pyridazin-3-one and 6- (4-amino-phenoxy) -2H-pyridazin-3-one derivatives as intermediates for thyroid hormone analogues | 马德里加尔制药公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11532830-B2 | Inexpensive metal-free organic redox flow battery (ORBAT) for grid-scale storage | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022087141-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | MADRIGAL PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087141-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | MADRIGAL PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051925-A1 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | CYP7A1, LIPC, CYP11B2 | DAO 2122/4885TYMP 1437/4885KDM4E 2280/4885 |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | SMO, GLI1, SHH | DAO 2000/4885TYMP 3270/4885KDM4E 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.